Strategic Partners A/S (FRA:1TB0)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.63M -27.2% |
| Revenue (ttm) | 40.66K +189.5% |
| Net Income | 180.17K |
| EPS | 4.26 |
| Shares Out | n/a |
| PE Ratio | 18.77 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4 |
| Open | 80.00 |
| Previous Close | 82.00 |
| Day's Range | 80.00 - 80.00 |
| 52-Week Range | 69.00 - 118.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Strategic Partners
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. Strategic Partners A/S was incorporated in 2009 and is based in Herlev, Denmark. [Read more]
News
Strategic Partners Quarterly report: H1 2026
Strategic Partners has published its H1 2026 quarterly earnings report on August 4, 2026.
Strategic Partners Annual report: H2 2025
Strategic Partners has published its H2 2025 annual report on March 30, 2026.
Strategic Partners Quarterly report: H1 2025
Strategic Partners has published its H1 2025 quarterly earnings report on September 16, 2025.
Strategic Partners Annual report: H2 2024
Strategic Partners has published its H2 2024 annual report on March 31, 2025.
Strategic Partners Quarterly report: H1 2024
Strategic Partners has published its H1 2024 quarterly earnings report on August 20, 2024.
Strategic Partners Annual report: H2 2023
Strategic Partners has published its H2 2023 annual report on March 27, 2024.
Strategic Partners Quarterly report: H1 2023
Strategic Partners has published its H1 2023 quarterly earnings report on September 12, 2023.
Strategic Partners Annual report: H2 2022
Strategic Partners has published its H2 2022 annual report on April 25, 2023.
Strategic Partners Quarterly report: H1 2022
Strategic Partners has published its H1 2022 quarterly earnings report on September 26, 2022.
Strategic Partners Annual report: H2 2021
Strategic Partners has published its H2 2021 annual report on June 7, 2022.
Strategic Partners Earnings Call Transcript: H1 2021
Strategic Partners Quarterly report: H1 2021
Strategic Partners has published its H1 2021 quarterly earnings report on August 30, 2021.
Strategic Partners Transcript: FDA Announcement
Strategic Partners Press release: FDA Announcement
Strategic Partners issued a press release on June 18, 2021, disclosing material business information to investors.
Strategic Partners Earnings Call Transcript: H2 2020
Strategic Partners Annual report: H2 2020
Strategic Partners has published its H2 2020 annual report on March 2, 2021.
Strategic Partners Slides: H2 2020
Strategic Partners has posted slides in relation to its H2 2020 quarterly earnings report, which was published on March 2, 2021.
Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Orphazyme A/S has today registered a capital increase of new ordinary shares and completed its global offering, consisting of an initial public offering of American Depositary Shares (“ADSs”) in the U...
Orphazyme files final prospectus in connection with a global offering, consisting of initial public offering of American Despositary Shares in the United States and concurrent private placement of ordinary shares in Europe
Orphazyme A/SCompany announcement No. 58/2020 ...
Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering
Orphazyme A/SCompany announcement No. 57/2020 ...
Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Orphazyme A/SCompany announcement No. 55/2020 ...
Orphazyme A/S provides update on previously announced global offering
Orphazyme A/SCompany announcement No. 54/2020 ...
Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
Orphazyme A/SCompany announcement No. 50/2020 ...
Denmark's Orphazyme files to go public on Nasdaq
Denmark-based Orphazyme A/S has filed to go public in the U.S., but has not yet determined how many shares it will offer.